Drug
Zuranolone clinical trials
Also written SAGE-217.
- studies test it
- 14
- open now
- 1
- in phase 3
- 8
- first study started
- 2016
Keep track of what changes. Save the zuranolone studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
- SAGE-217
- 10
Studies by the year they started
14 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 3 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 4
- Phase 3
- 8
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 1
Studies
Open first, then newest update. How each study uses zuranolone is read from its arms, and is right about nine times in ten.
Testing it · 14
- Allopregnanolone (Zuranolone) in Post-stroke DepressionRecruitingPhase 2Duke UniversityNCT06759558Written as Zuranolone
- Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)CompletedPhase 1BiogenNCT05655507Written as Zuranolone
- A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)CompletedPhase 3BiogenNCT03864614Written as SAGE-217
- A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive DisorderCompletedPhase 3BiogenNCT04476030Written as SAGE-217
- A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)CompletedPhase 3BiogenNCT04442490Written as SAGE-217
- A Study to Evaluate SAGE-217 in Participants With Severe Postpartum DepressionCompletedPhase 3BiogenNCT02978326Written as SAGE 217 30 mg Capsules
- A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive EpisodeCompletedPhase 2BiogenNCT03692910Written as SAGE-217
- A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)CompletedPhase 3BiogenNCT04442503Written as SAGE-217
- A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Using an Insomnia ModelCompletedPhase 1BiogenNCT03284931Written as SAGE-217 high dose
- A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive DisorderCompletedPhase 3BiogenNCT03672175Written as SAGE-217
- A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive DisorderTerminatedPhase 3BiogenNCT04007367Written as SAGE-217
- A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and InsomniaTerminatedPhase 3BiogenNCT03771664Written as SAGE-217
- A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive DisorderCompletedPhase 2BiogenNCT03000530Written as SAGE-217
- A Study to Evaluate SAGE-217 in Participants With Essential TremorCompletedPhase 2BiogenNCT02978781Written as SAGE-217
Given in every arm · 1 — zuranolone is usual care beside what is tested
Codes
What other systems call zuranolone · ClinicalTrials.gg INT001175
- MeSH (NLM) C000634505zuranoloneConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 7ZW49N180BZURANOLONEConfirmed FDA, NLM, Wikidata
- Wikidata Q48862264zuranoloneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171709ZuranoloneOne source FDA
- DrugBank DB15490One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000634505 | zuranolone | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 7ZW49N180B | ZURANOLONE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q48862264 | zuranolone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171709 | Zuranolone | One source FDA |
| DrugBank | DB15490 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.